ABL Diagnostics
ABL Diagnostics is a French public molecular diagnostics company that develops CE-IVD assays, sequencing-based genotyping kits (DeepChek), real-time PCR tests (UltraGene), and clinical software for infectious disease drug resistance testing, serving clinical pathology labs, hospitals, and pharmaceutical companies globally through direct sales and exclusive distributors.
- Company typePublic
- Founded2000
- HeadquartersWoippy, France
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What ABL Diagnostics does
ABL Diagnostics S.A. is a French publicly traded molecular diagnostics company (Euronext Paris: ABLD) headquartered in Woippy, France, with manufacturing operations in Marseille and Luxembourg. The company develops and commercializes CE-IVD and RUO molecular diagnostic assays, software, and laboratory automation for infectious disease genotyping and drug resistance testing, organized around two proprietary technology brands: DeepChek (genotyping through NGS and Sanger sequencing) and UltraGene (real-time PCR detection and quantification). ABL's product portfolio spans HIV, tuberculosis, SARS-CoV-2, viral hepatitis B and C, HPV, CMV, HSV, BKV, RSV, and Salmonella, supported by companion bioinformatics software (ViroScore, BacterioChek, MicrobioChek, DeepChek Software) and the Nadis CE-marked EMR system used in more than 200 French hospitals for HIV and viral hepatitis patient management. The company holds unique regulatory certifications including the only CE-IVD marked full-genome HIV-1 genotyping assay worldwide, ISO 13485:2016 certification, and a renewed US Patent (8,859,198 B2) for hepatitis B genotyping.
ABL generates revenue through three streams: (1) molecular biology assays and kits sold via one-time licenses through direct sales and exclusive distributors globally; (2) recurring software license subscriptions for DeepChek, ViroScore, and BacterioChek platforms; and (3) clinical services and CRO revenue through its CDL Pharma subsidiary, including a recently signed multi-year neurodegenerative disease contract worth up to €2.7M through 2031. Distribution is hybrid: an in-house sales team and a wholly-owned US subsidiary (AdvancedDx Biological Laboratories USA Inc., operating since 2019) complemented by an exclusive distributor network active on all continents, with strategic supplier agreements with Thermo Fisher Scientific, QIAGEN, Roche, and Illumina securing the supply chain. Reported H1 2025 revenue was €2.85M with DeepChek HIV products growing 73% YoY, and external analyst projections point to approximately €12.2M in 2026 revenue.
ABL Diagnostics firmographics
Firmographics- Name
- ABL Diagnostics
- Legal name
- ABL Diagnostics S.A.
- Website
- https://abldiagnostics.com
- Company type
- Public
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- ABL Diagnostics is a French public molecular diagnostics company that develops CE-IVD assays, sequencing-based genotyping kits (DeepChek), real-time PCR tests (UltraGene), and clinical software for infectious disease drug resistance testing, serving clinical pathology labs, hospitals, and pharmaceutical companies globally through direct sales and exclusive distributors.
- Ownership category
- akta.pro rank
ABL Diagnostics industry classification
Industry- Product category
- Molecular Diagnostics
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Software Publishers (513210)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD)
- akta.pro secondary industries
- Microbiology & Infectious Disease Diagnostics (Culture/ID/AST) (HLAHAAAC), Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels) (HLAAALAC), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF)
Keywords
Where ABL Diagnostics is headquartered
LocationHeadquarters
- HQ city
- Woippy
- HQ country
- France
- HQ region
- Europe
Offices5 records
Markets served
ABL Diagnostics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure
Revenue model
- Molecular Biology Assays and Kits: ABLD generates recurring revenues from molecular biology products including DeepChek genotyping kits (NGS and Sanger-based) and UltraGene real-time PCR assays covering infectious disease applications including HIV, SARS-CoV-2, tuberculosis, viral hepatitis B and C, 16S/18S RNA, and other viral and bacterial targets. Revenue is generated through direct sales and exclusive distributors.
- Software Licenses and Analytics: DeepChek software, ViroScore-HIV, BacterioChek-TB, and other downstream analysis software platforms are commercialized with annual software licenses. DeepChek HIV products grew 73% year-on-year to €1.20 million in H1 2025.
- Clinical Services and CRO: ABL Diagnostics operates clinical services in partnership with CDL Pharma, generating progressive revenue from multi-year international clinical programs. Services include neurodegenerative disease research, laboratory services, and third-party clinical trial management through the US subsidiary.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Laboratory and research products sold via direct inquiry and distributor network |
Go-to-market motion3 records
Distribution channels6 records
Marketing channels7 records
ABL Diagnostics product offering
Product offeringCore offering
ABL Diagnostics develops, manufactures, and commercializes molecular diagnostic kits and supporting software for infectious disease genotyping. Its portfolio centers on two proprietary platforms: DeepChek (genotyping through next-generation sequencing and Sanger sequencing) and UltraGene (real-time PCR molecular detection). The company also offers companion analysis software (ViroScore, DeepChek Software, MicrobioChek, BacterioChek, SeqHepB), the Nadis electronic medical record system, specimen collection kits, and laboratory automation robots.
Product overview
ABL Diagnostics offers a comprehensive molecular diagnostics portfolio organized around two core technology brands: DeepChek for genotyping through next-generation sequencing (NGS) and Sanger sequencing, and UltraGene for real-time PCR detection and quantification. The DeepChek platform provides assays for HIV (whole genome, integrase, protease/reverse transcriptase), tuberculosis, SARS-CoV-2, HCV, HBV, and other pathogens, supported by companion software including DeepChek Software, ViroScore, MicrobioChek, and BacterioChek. The UltraGene brand covers syndromic qPCR panels for respiratory, gastrointestinal, STI, hepatitis, and other infections. Digital solutions include Nadis electronic medical records (CE-marked, used in 200+ French hospitals) and SeqHepB for hepatitis B analysis. The company also provides specimen collection kits (MediaChek), liquid handling automation (DeepChek and OpenChek pipetting robots), and supports multiple NGS platforms including Illumina iSeq/MiSeq, Element Biosciences AVITI, MGI DNBSEQ, and VELA Sentosa through its platform-agnostic approach.
Differentiator
Problem solved
Functional benefit
Brands
- DeepChek: Genotyping through NGS and Sanger sequencing technology for HIV, SARS-CoV-2, HCV, TB, and other pathogens
- UltraGene
- MediaChek
- Nadis
- ViroScore
- BacterioChek
- MicrobioChek
- CRISPRChek
- HybridChek
- SeqHepB
Products and services
- DeepChek Whole Genome HIV-1 Genotyping Assay CE-IVD marked whole-genome HIV-1 genotyping assay that enables comprehensive resistance profiling across all HIV-1 genomic regions. Validated for use in routine diagnostic laboratories.
- DeepChek Protease/Reverse Transcriptase Genotyping Assay
Quantifiable outcome
- DeepChek HIV products grew 73% year-on-year to €1.20 million in H1 2025
- +2 more outcomes
Companies that use ABL Diagnostics
Customer profileNamed customers6 records
Segments5 records
Ideal customer profiles5 records
ABL Diagnostics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration10 records
AI capability8 records
Feature7 records
ABL Diagnostics partnerships and signals
Strategic signalPartnerships
15 partnerships are on record, tiered core, strategic and regional.
- CDL PharmacoreABL Diagnostics and CDL Pharma secured a multi-year international contract with a European pharmaceutical company for neurodegenerative disease research services involving 30 centers across 11 countries. Services are operated by CDL Pharma and distributed by ABL Diagnostics, with total potential value of approximately €2.7 million through 2031, with initial payment exceeding €100,000. The partnership generates progressive revenue based on clinical program performance and enhances visibility of future revenues.
- Element BiosciencesstrategicABL Diagnostics advanced its platform-agnostic NGS strategy by verifying DeepChek assays on Element Biosciences' AVITI sequencer, expanding the range of compatible NGS platforms for ABLD's infectious disease genotyping solutions.
- Thermo Fisher Scientific, QIAGEN, Roche, IlluminacoreABL Diagnostics reinforced strategic supplier agreements with multiple leading life science and molecular biology companies including Thermo Fisher Scientific, QIAGEN, Roche, Illumina, and others to secure a robust supply chain supporting commercial growth. The renewed agreements provide improved commercial conditions including more competitive pricing, optimized contractual terms, and enhanced supply security, strengthening the company's cost structure and improving margin expectations for 2026.
- seqWellstrategicABL Diagnostics announced a partnership with seqWell to develop a new library preparation solution for next-generation sequencing (NGS) of infectious diseases. The new product, integrated into ABL's DeepChek platform, aims to reduce hands-on time, improve performance, and support high-volume microbiology labs, particularly for HIV and tuberculosis genotyping.
- ELTA 90 Medical ScienceregionalABL Diagnostics and ELTA 90 Medical Science won a tender to deliver a whole genome HIV genotyping solution in Montenegro, marking a significant upgrade in the country's HIV drug resistance testing capabilities. The project combines ABL's HIV assays and bioinformatics software with ELTA 90's Illumina-based NGS systems to create a scalable, high-precision platform supporting Montenegro's move to adopt state-of-the-art HIV surveillance.
- Eurobio Scientific (France)regionalABL Diagnostics signed an exclusive distribution agreement with Eurobio Scientific for its VELA product line in the French public hospital market. The partnership aims to improve access to advanced molecular diagnostics and enhance customer service, leveraging Eurobio Scientific's existing distribution channels in France.
- VELA DiagnosticscoreABL Diagnostics and VELA Diagnostics expanded their strategic partnership involving the transition of reagent supply to ABL Diagnostics for the EMEA region and integration of VELA Europe's team into ABL Diagnostics. They also validated automation of DeepChek assays on the Sentosa platform, enhancing infectious disease genotyping capabilities across the EMEA region.
- Université Grenoble Alpes and CHU Grenoble AlpesstrategicABL Diagnostics expanded its collaboration with Université Grenoble Alpes and CHU Grenoble Alpes to develop and provide HCV genotyping and resistance testing solutions based on NGS technology. The partnership offers a validated portfolio of DeepChek HCV assays and bioinformatics software for research applications, aiming to enhance understanding of viral diversity and drug resistance while aligning with ABL Diagnostics' broader goal of advancing viral hepatitis molecular diagnostics.
- Riken Genesis (Japan)regionalABL Diagnostics signed an exclusive distribution agreement with Riken Genesis Co., Ltd. for its DeepChek and UltraGene molecular assays across laboratories in Japan, strengthening ABLD's diagnostics portfolio in the Asia-Pacific region.
- MGI TechstrategicMGI and ABL Diagnostics announced a partnership showcased at ESCMID Global 2024, integrating ABLD's DeepChek technology with MGI's DNBSEQ-E25 sequencer for the European and African market, providing microbiology labs with an end-to-end NGS solution.
- Complete Genomics LLC (USA)regionalAdvancedDx Biological Laboratories USA Inc., an affiliate of ABL Diagnostics, executed a co-marketing agreement with Complete Genomics LLC to co-promote Next Generation Sequencing microbiology solutions in the USA market.
- Medline Industries LP (USA)regionalAdvancedDx Biological Laboratories USA Inc. executed a non-exclusive distribution agreement with Medline Industries LP to promote and commercialize ABLD's NGS Prep Kits in the United States, expanding reach in the US distribution channel.
- VELA Diagnostics USA Inc.strategicAdvancedDx Biological Laboratories USA Inc. expanded its logistics and storage capacity through a new agreement with VELA Diagnostics USA Inc. for supporting and managing third-parties' clinical trials in the USA.
- Roche Diagnostics SpainregionalABL Diagnostics strengthened its historic partnership with Roche Diagnostics Spain to extend its offering to the Spanish market, reinforcing its position as a leader in HIV genotyping in Spain.
- IlluminacoreABL Diagnostics signed a Channel Partners Agreement with Illumina to offer combined DeepChek products on the iSeq 100 and MiSeq next-generation sequencing platforms to microbiology laboratories in mainland France, Belgium, and Luxembourg.
Scale indicators10 records
Recent moves9 records
Expansion highlights8 records
ABL Diagnostics competitors and assessment
Company assessmentBroad incumbents
- bioMérieux: French-headquartered microbiology and molecular diagnostics leader with the BIOFIRE FilmArray syndromic panels and VITEK MS identification systems. Comparable as a microbiology-focused incumbent with overlapping infectious disease menu and overlapping hospital-customer footprint in Europe.
- DiaSorin: Italian diagnostics company with a growing molecular infectious disease portfolio (LIAISON MDX platform) including respiratory and STI panels. Comparable as a European-headquartered mid-cap competitor expanding automated molecular offerings adjacent to ABL's infectious disease focus.
- Hologic: Markets the Panther and Panther Fusion fully automated molecular diagnostic systems used for sexually transmitted infections, HPV, and viral load testing. Comparable as a broad incumbent with overlapping infectious disease menu and significant commercial reach in women's health and hospital labs.
- Abbott Molecular: Operates the m2000 and Alinity m automated molecular diagnostic systems serving HIV, HCV, HBV, and CT/NG testing. Comparable as a large incumbent in infectious disease molecular diagnostics competing for the same hospital and reference-lab customers as ABL's DeepChek assays.
- QIAGEN: Global molecular diagnostics and life science tools leader with HIV/HCV viral load assays (artus, QIAsymphony) and a broad sample-prep franchise. Comparable to ABL Diagnostics as both an incumbent in molecular infectious disease testing and a strategic supplier (reagent partnership) to ABL.
- Bio-Rad Laboratories: Major life science tools and clinical diagnostics company with the QX200 Droplet Digital PCR system and a broad molecular biology reagent portfolio. Comparable as a broad incumbent in molecular biology tools and as a supplier/distribution peer in the same research and clinical workflows as ABL.
- Bruker (Hain Lifescience): Acquired Hain Lifescience, maker of the Fluorotype and GenoType line probe assays for TB drug resistance detection. Comparable as a TB drug resistance testing peer offering molecular alternatives to ABL's DeepChek 13-Plex KB assay and upcoming whole-genome TB NGS solution.
- Roche Diagnostics: Owns the cobas automated molecular platform widely used for HIV and HCV viral load testing in hospitals and reference labs. Comparable as the dominant incumbent ABL competes against in HIV diagnostics; also a strategic supplier to ABL.
- Cepheid (Danaher): GeneXpert system is the de facto standard for rapid MTB/RIF tuberculosis drug resistance detection worldwide. Directly comparable to ABL's DeepChek TB 13-Plex KB assay and whole-genome TB NGS solution as the dominant automated TB resistance testing platform.
Direct peers
- Seegene: Korea-based molecular diagnostics company specializing in multiplex syndromic PCR assays for infectious diseases (respiratory, STI, gastrointestinal). Directly comparable to ABL's UltraGene real-time PCR assays in syndromic infectious disease menu and similar hospital/reference lab target customers.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
ABL Diagnostics social profiles
Digital presenceABL Diagnostics compliance and trust
Trust signalCompliance4 records
ABL Diagnostics financial estimates
Financial estimateRevenue estimate
Valuation estimate
ABL Diagnostics leadership team
Management profileNumber of profiles
Profiles5 records
ABL Diagnostics subsidiaries and ownership
Company hierarchySubsidiaries3 records
ABL Diagnostics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ABL Diagnostics M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ABL Diagnostics
What does ABL Diagnostics do?
ABL Diagnostics develops, manufactures, and commercializes molecular diagnostic kits and supporting software for infectious disease genotyping. Its portfolio centers on two proprietary platforms: DeepChek (genotyping through next-generation sequencing and Sanger sequencing) and UltraGene (real-time PCR molecular detection). The company also offers companion analysis software (ViroScore, DeepChek Software, MicrobioChek, BacterioChek, SeqHepB), the Nadis electronic medical record system, specimen collection kits, and laboratory automation robots.
Is ABL Diagnostics a public or private company?
ABL Diagnostics is a public company. It is classified as public and is currently operating.
When was ABL Diagnostics founded?
ABL Diagnostics was founded in 2000. It employs 11 to 50 people.
Where is ABL Diagnostics based?
ABL Diagnostics is headquartered in Woippy, France, in the Europe region.
How does ABL Diagnostics make money?
Three revenue lines are on record. Molecular Biology Assays and Kits are the primary driver. The others are software Licenses and Analytics and clinical Services and CRO.
Who are ABL Diagnostics's main competitors?
Broad incumbents on record are bioMérieux, DiaSorin, Hologic, Abbott Molecular, QIAGEN, Bio-Rad Laboratories, Bruker (Hain Lifescience), Roche Diagnostics and Cepheid (Danaher). Seegene is listed as a direct peer.
Does ABL Diagnostics have an API?
No public API is recorded for ABL Diagnostics.
What industry is ABL Diagnostics in?
ABL Diagnostics's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD), with a secondary code of HLAHAAAC, Microbiology & Infectious Disease Diagnostics (Culture/ID/AST). Its NAICS code is 621511 and its SIC code is 2835.